| The rising burden of cancer in the developing world P Kanavos Annals of oncology 17, viii15-viii23, 2006 | 659 | 2006 |
| Assessing the economic challenges posed by orphan drugs MF Drummond, DA Wilson, P Kanavos, P Ubel, J Rovira International journal of technology assessment in health care 23 (1), 36-42, 2007 | 358 | 2007 |
| Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries A Angelis, A Lange, P Kanavos The European Journal of Health Economics 19, 123-152, 2018 | 316 | 2018 |
| Socio-economic burden of rare diseases: a systematic review of cost of illness evidence A Angelis, D Tordrup, P Kanavos Health Policy 119 (7), 964-979, 2015 | 315 | 2015 |
| Encouraging the use of generic medicines: implications for transition economies DR King, P Kanavos Croatian medical journal 43 (4), 462-469, 2002 | 301 | 2002 |
| Ensuring value for money in health care: the role of health technology assessment in the European Union C Sorenson, M Drummond, P Kanavos WHO Regional Office Europe, 2008 | 296 | 2008 |
| Early chronic kidney disease: diagnosis, management and models of care OJ Wouters, DJ O'donoghue, J Ritchie, PG Kanavos, AS Narva Nature Reviews Nephrology 11 (8), 491-502, 2015 | 284 | 2015 |
| Diabetes expenditure, burden of disease and management in 5 EU countries P Kanavos, S van den Aardweg, W Schurer LSE health, London school of Economics 113, 2012 | 242 | 2012 |
| Multiple criteria decision analysis (MCDA) for evaluating new medicines in health technology assessment and beyond: the advance value framework A Angelis, P Kanavos Social Science & Medicine 188, 137-156, 2017 | 222 | 2017 |
| Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden A Ferrario, P Kanavos Social science & medicine 124, 39-47, 2015 | 194 | 2015 |
| Competition in off-patent drug markets: Issues, regulation and evidence P Kanavos, J Costa-Font, E Seeley Economic policy 23 (55), 500-544, 2008 | 192 | 2008 |
| Managed entry agreements for pharmaceuticals: the European experience A Ferrario, P Kanavos EMINet, 2013 | 170 | 2013 |
| Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ... Globalization and health 9, 1-12, 2013 | 166 | 2013 |
| Reference pricing for drugs: is it compatible with US health care? P Kanavos, U Reinhardt Health Affairs 22 (3), 16-30, 2003 | 163 | 2003 |
| The implementation of managed entry agreements in Central and Eastern Europe: findings and implications A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ... Pharmacoeconomics 35, 1271-1285, 2017 | 161 | 2017 |
| Comparing generic drug markets in Europe and the United States: prices, volumes, and spending OJ Wouters, PG Kanavos, M McKee The Milbank Quarterly 95 (3), 554-601, 2017 | 161 | 2017 |
| Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom SG Morgan, M McMahon, C Mitton, E Roughead, R Kirk, P Kanavos, ... Health Affairs 25 (2), 337-347, 2006 | 159 | 2006 |
| Pharmaceutical parallel trade in Europe: stakeholder and competition effects P Kanavos, J Costa-Font Economic policy 20 (44), 758-798, 2005 | 142 | 2005 |
| Medical technology procurement in Europe: A cross-country comparison of current practice and policy C Sorenson, P Kanavos Health policy 100 (1), 43-50, 2011 | 129 | 2011 |
| Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ... Retina 33 (10), 2012-2017, 2013 | 128 | 2013 |
